Tuesday, August 7, 2012

Another great quarter at TARO

Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article

I love TARO's low competition business. Sales increased 47% compared to last year. EBIDTA is $79.0 million.
So this year's EBIDTA will be around $320 million.  Yet TARO trades at EV/Est EBIDTA of ~5.

The Company recently received two approvals from the U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Applications (“ANDAs”) for Clobetasol Propionate Lotion, 0.05% and Escitalopram Oxalate Oral Solution, 5mg (base)/5mL. It one ANDA and one New Drug Application (“NDA”) with the FDA. With this, ANDAs representing fifteen products as well as two NDAs await FDA approval


No comments:

Post a Comment